Severe graves ophthalmopathy accompanied by HTLV-1-associated uveitis (HAU) and anti-neutrophil cytoplasmic antibody-related vasculitis: a case report and a review of the literature of HAU with Graves disease.

A 50-year-old woman was admitted because of severe exophthalmos associated with Graves disease. She underwent methimazole (MMI) and methylprednisolone pulse therapy against exophthalmos. She noticed photophobia and blurred vision 3 weeks after the start of pulse therapy and she was diagnosed as having uveitis. Methylprednisolone pulse therapy was performed again for both exophthalmos and uveitis, followed by daily administration of 20 mg of prednisolone and instillation of betamethasone for 2 weeks and the uveitis was improved. Western blot analysis confirmed that human T lymphotropic virus type 1 (HTLV-1) antibody was present in her serum. Propylthiouracil was substituted for MMI and HTLV-1-associated uveitis (HAU) has not recurred. Six months after the beginning of administration of PTU, anti-neutrophil cytoplasmic antibody-related vasculitis developed in the patient. We review 43 cases of HAU with Graves disease, including the present case, in the literature. Only 2 of 27 cases (except unknown cases) (7.4%) had Graves ophthalmopathy. To the best of our knowledge, there has been no investigation of HAU and Graves ophthalmopathy.

[1]  M. Akaike,et al.  Graves' disease in HTLV-I carriers , 1995, Journal of Molecular Medicine.

[2]  C. Marcocci,et al.  Management of Graves' ophthalmopathy: reality and perspectives. , 2000, Endocrine reviews.

[3]  M. Schwarz,et al.  Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. , 1999, Chest.

[4]  M. Matsuoka,et al.  Provirus Load in Patients with Human T‐Cell Leukemia Virus Type 1 Uveitis Correlates with Precedent Graves' Disease and Disease Activities , 1998, Japanese journal of cancer research : Gann.

[5]  M. Mochizuki,et al.  Immunologic and virologic characterization of the primary infiltrating cells in the aqueous humor of human T-cell leukemia virus type-1 uveitis. Accumulation of the human T-cell leukemia virus type-1-infected cells and constitutive expression of viral and interleukin-6 messenger ribonucleic acids. , 1997, Investigative ophthalmology & visual science.

[6]  M. Fujishima,et al.  Human T-lymphotropic virus type I-associated uveitis in patients with Graves' disease treated with methylmercaptoimidazole. , 1995, The Journal of clinical endocrinology and metabolism.

[7]  G. Khursigara,et al.  Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. , 1994, Science.

[8]  H. Hayashi,et al.  [A multicenter clinico-epidemiological study of HTLV-I associated uveitis]. , 1994, Nippon Ganka Gakkai zasshi.

[9]  Y. Shishiba,et al.  Development of Graves' ophthalmopathy and uveitis after radioiodine therapy for Graves' disease in a patient with HTLV-I associated myelopathy (HAM). , 1994, Internal medicine.

[10]  Y. Ikeda.  [A case of an HLTV-I carrier associated with Basedow's disease and uveitis]. , 1994, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[11]  M. Mochizuki,et al.  Human T lymphotropic virus type 1 uveitis after Graves' disease. , 1994, The British journal of ophthalmology.

[12]  A. Okubo,et al.  HTLV-I associated uveitis and hyperthyroidism. , 1994, Japanese journal of ophthalmology.

[13]  R. Goldschmeding,et al.  Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy , 1993, The Lancet.

[14]  M. Mochizuki,et al.  Clinical and immunologic features of human T-cell lymphotropic virus type I uveitis. , 1993, American journal of ophthalmology.

[15]  N. Ohba,et al.  Clinical features of HTLV-I associated uveitis. , 1993, The British journal of ophthalmology.

[16]  F. Dove.  Drug-induced lupus , 1982 .

[17]  T. Inui,et al.  HTLV‐I infection in patients with autoimmune thyroiditis (Hashimoto's thyroiditis) , 1992, Journal of medical virology.

[18]  C. Mora,et al.  HTLV-1 AND POLYMYOSITIS IN JAMAICA , 1989, The Lancet.

[19]  M. Schroll,et al.  RECOMMENDED DIETARY ALLOWANCES FOR EUROPE , 1989, The Lancet.

[20]  I. Maruyama,et al.  CHRONIC INFLAMMATORY ARTHROPATHY ASSOCIATED WITH HTLV-I , 1989, The Lancet.

[21]  N. Monplaisir,et al.  T-LYMPHOCYTE ALVEOLITIS, TROPICAL SPASTIC PARESIS, AND SJÖGREN SYNDROME , 1988, The Lancet.

[22]  M. Sugimoto,et al.  T-LYMPHOCYTE ALVEOLITIS IN HTLV-I-ASSOCIATED MYELOPATHY , 1987, The Lancet.

[23]  S. Izumo,et al.  Chronic progressive myelopathy associated with elevated antibodies to human T‐lymphotropic virus type I and adult T‐cell leukemialike cells , 1987, Annals of neurology.

[24]  Mitsuhiro Osame,et al.  HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY , 1986, The Lancet.

[25]  T. Sanke,et al.  Glucagon binding autoantibodies in a patient with hyperthyroidism treated with methimazole. , 1983, The Journal of clinical endocrinology and metabolism.

[26]  M. Yoshida,et al.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Yeo,et al.  Ophthalmic Graves's disease: natural history and detailed thyroid function studies. , 1977, British medical journal.

[28]  A. Noguchi,et al.  Spontaneous hypoglycemia with insulin autoimmunity in Graves' disease. , 1974, Annals of internal medicine.

[29]  Backworth Tc.  Psychiatric Reports: whether and how. , 1966 .

[30]  GEORGE Clark Cathcart. , 1951, Lancet.

[31]  R. Magendie,et al.  History of a Case of Hydrophobia, treated at the Hotel Dieu at Paris, by an injection of water into the veins. , 1823 .